(Q46774789)

25 December 2017

title

Bcr-Abl induces autocrine IGF-1 signaling (English)

1 reference

25 December 2017

author name string

A Lakshmikuttyamma

1

1 reference

25 December 2017

E Pastural

2

1 reference

25 December 2017

N Takahashi

3

1 reference

25 December 2017

K Sawada

4

1 reference

25 December 2017

D P Sheridan

5

1 reference

25 December 2017

J F DeCoteau

6

1 reference

25 December 2017

C R Geyer

7

1 reference

25 December 2017

language of work or name

English

0 references

publication date

4 February 2008

1 reference

25 December 2017

published in

Oncogene

1 reference

25 December 2017

volume

27

1 reference

25 December 2017

issue

27

1 reference

25 December 2017

page(s)

3831-3844

1 reference

25 December 2017

https://scigraph.springernature.com/pub.10.1038/onc.2008.8

exact match

0 references

cites work

Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

The IGF‐1 receptor in cancer biology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Functional significance of type 1 insulin-like growth factor-mediated nuclear translocation of the insulin receptor substrate-1 and beta-catenin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Cross-talk between IGF-I and TGF-beta signaling pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

JURL-MK1 (c-kit(high)/CD30-/CD40-) and JURL-MK2 (c-kit(low)/CD30+/CD40+) cell lines: 'two-sided' model for investigating leukemic megakaryocytopoiesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

The role of STAT proteins in growth hormone signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Characterization of insulin-like growth factor I receptors on human erythroleukemia cell line (K-562 cells)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Growth factor receptor interplay and resistance in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Growth hormone insensitivity associated with a STAT5b mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Insulin-like growth factor I stimulates erythropoiesis in hypophysectomized rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Numerous growth factors, cytokines, and chemokines are secreted by human CD34+ cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Enhancement of erythropoiesis in vitro by human growth hormone is mediated by insulin-like growth factor I

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Enhancement of human granulopoiesis in vitro by biosynthetic insulin-like growth factor I/somatomedin C and human growth hormone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

RIZ1 repression is associated with insulin-like growth factor-1 signaling activation in chronic myeloid leukemia cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Receptor binding and mitogenic effects of insulin and insulinlike growth factors I and II for human myeloid leukemic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Insulin-like growth factors and neoplasia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Disrupting insulin-like growth factor signaling as a potential cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Transcriptional responses to polypeptide ligands: the JAK-STAT pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Comparative effects of insulin-like growth factor II (IGF-II) and IGF-II mutants specific for IGF-II/CIM6-P or IGF-I receptors on in vitro hematopoiesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

The insulin-like growth factor system in regulation of normal and malignant hematopoiesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Constitutive expression of IL-1 beta, M-CSF and c-fms during the myeloid blastic phase of chronic myelogenous leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

A monoclonal antibody against CD148, a receptor-like tyrosine phosphatase, inhibits endothelial-cell growth and angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

IGF-I receptor signalling in transformation and differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Growth and differentiation signals by the insulin-like growth factor 1 receptor in hemopoietic cells are mediated through different pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Identification of a distal STAT5-binding DNA region that may mediate growth hormone regulation of insulin-like growth factor-I gene expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

Mechanisms of growth hormone (GH) action. Identification of conserved Stat5 binding sites that mediate GH-induced insulin-like growth factor-I gene activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

New assignments for multitasking signal transduction inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.8

31 March 2020

Identifiers

DOI

10.1038/ONC.2008.8

1 reference

25 December 2017

1 reference

25 December 2017